Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)

PHASE4UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

October 31, 2016

Conditions
Sarcoidosis
Interventions
DRUG

Roflumilast

Roflumilast

DRUG

Placebo

Placebo one a day

Trial Locations (1)

45267

University of Cincinnati, Cincinnati

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

The Cleveland Clinic

OTHER

collaborator

University of Pittsburgh

OTHER

collaborator

University of Illinois at Chicago

OTHER

collaborator

Henry Ford Health System

OTHER

collaborator

Albany Medical College

OTHER

lead

University of Cincinnati

OTHER

NCT01830959 - Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) | Biotech Hunter | Biotech Hunter